Loading…
Kailera Therapeutics, Inc. is projected to decline to $16.76 by 2027, a -2% move from its current price of $17.05. KLRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $16.55 | $17.05 | $17.55 | -0.03% |
| Aug 2 | $16.35 | $17.04 | $17.76 | -0.05% |
| Aug 3 | $16.19 | $17.04 | $17.92 | -0.08% |
| Aug 4 | $16.06 | $17.03 | $18.06 | -0.11% |
| Aug 5 | $15.95 | $17.03 | $18.18 | -0.13% |
| Aug 6 | $15.85 | $17.02 | $18.29 | -0.16% |
| Aug 7 | $15.75 | $17.02 | $18.39 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.75 | $17.02 | $18.39 | -0.19% |
| Week 2 | $15.22 | $16.99 | $18.95 | -0.37% |
| Week 3 | $14.83 | $16.95 | $19.39 | -0.56% |
| Week 4 | $14.50 | $16.92 | $19.76 | -0.75% |
| Week 5 | $14.21 | $16.89 | $20.08 | -0.93% |
| Week 6 | $13.95 | $16.86 | $20.38 | -1.12% |
| Week 7 | $13.71 | $16.83 | $20.65 | -1.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations.
The company was founded in 2024 and is based in Waltham, Massachusetts.
KLRA is currently trading at $17.91, with a market cap of $2.32B and a rank of 1833. The stock sits in the Healthcare sector as a clinical-stage biopharmaceutical company focused on obesity-related conditions.
Technically, the stock’s picture remains bearish, with RSI14 at 40 and the price trading below the 50-day simple moving average of $20.84. Near-term levels show a defined support at $17.91 and resistance at $23.30.
The 30-day price range spans $14.28 to $22.46, illustrating a broad swing in recent moves. Annualized volatility is high at 70%, underscoring elevated risk in the near term.
A major floor 26.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 36.7% above — a clean break opens room to run.
A major ceiling 52.5% above — clearing it would confirm fresh momentum.
Key KLRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KLRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.17 | Sell | $17.18 | Sell |
| MA 10 | $17.59 | Sell | $17.69 | Sell |
| MA 20 | $19.17 | Sell | $18.59 | Sell |
| MA 50 | $20.18 | Sell | $20.16 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.40 | Neutral |
| Stoch RSI (14) | 25.59 | Neutral |
| CCI (20) | -84.00 | Neutral |
| Williams %R (14) | -90.40 | Info |
| MACD (12,26,9) | -0.19 | Sell |
| ROC (12) | -10.31 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 9.60 | Buy |
| TRIX (15) | -0.61 | Sell |
| Awesome (5,34) | -2.56 | Sell |
| Ultimate (7,14,28) | 26.24 | Buy |
| Momentum (10) | -1.27 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 16.73 | Buy |
| ADX (14) | 20.47 | Sell |
| ATR (14) | 0.57 | Info |
The 30-day picture is bearish, with RSI14 at 40 indicating residual selling pressure and a cautious near-term stance.
The price is below the 50-day SMA of $20.84, placing near-term momentum in a downbeat context relative to short-term trend lines. Key levels to watch are support at $17.91 and resistance at $23.30, with the 30-day range defined from $14.28 to $22.46.
In this setup, upside is contingent on momentum turning above resistance and reducing volatility, while break below the tight support could invite renewed selling pressure.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.74 | $17.05 | $21.81 | 0% | Neutral | |
| $12.63 | $16.76 | $23.91 | -2% | Neutral | |
| $12.36 | $17.22 | $25.98 | +1% | Neutral | |
| $12.93 | $18.76 | $29.53 | +10% | Neutral | |
| $14.64 | $22.04 | $35.93 | +29% | Bullish | |
| $13.57 | $21.13 | $35.51 | +24% | Bullish | |
| $12.23 | $19.67 | $33.97 | +15% | Neutral | |
| $12.85 | $21.30 | $37.69 | +25% | Bullish | |
| $12.06 | $20.58 | $37.23 | +21% | Bullish | |
| $12.70 | $22.30 | $41.18 | +31% | Bullish | |
| $13.11 | $26.30 | $52.86 | +54% | Bullish | |
| $23.80 | $52.89 | $119.83 | +210% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.74 | $17.05 | $19.93 | +0.00% |
| August 2026 | $13.82 | $16.43 | $20.15 | -3.62% |
| September 2026 | $13.81 | $16.64 | $20.83 | +1.25% |
| October 2026 | $14.12 | $17.20 | $21.89 | +3.38% |
| November 2026 | $13.82 | $16.99 | $21.91 | -1.23% |
| December 2026 | $13.47 | $16.71 | $21.81 | -1.66% |
Click any year to see its month-by-month KLRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KLRA to range from $16.74 to $21.81 through 2026. The $17.05 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KLRA price prediction for 2027 points to an average of $16.76 (low $12.63, high $23.91) — a potential decline of -2% on today's $17.05. Price action looks broadly range-bound.
In 2028, KLRA is projected to trade between $12.36 and $25.98, averaging $17.22 — a potential gain of +1% from today's $17.05. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
Kailera Therapeutics, Inc.'s 2029 outlook centres on $18.76, within a $12.93 to $29.53 range. That is up +9% on the projected 2028 average. That marks a +10% change versus current levels. Price action looks broadly range-bound.
By 2030, KLRA could reach as high as $35.93, with a base case around $22.04 and support toward $14.64 — roughly +29% from $17.05. Buyers look set to stay in control over this stretch.
Expect KLRA to range from $13.57 to $35.51 through 2031. The $21.13 average target implies a +24% move from current prices. That is -4% versus the projected 2030 average. Momentum favours further upside here.
The KLRA price prediction for 2032 points to an average of $19.67 (low $12.23, high $33.97) — a potential gain of +15% on today's $17.05. A consolidation phase looks the most probable path here.
In 2033, KLRA is projected to trade between $12.85 and $37.69, averaging $21.30 — a potential gain of +25% from today's $17.05. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Kailera Therapeutics, Inc.'s 2034 outlook centres on $20.58, within a $12.06 to $37.23 range. That is -3% versus the projected 2033 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KLRA could reach as high as $41.18, with a base case around $22.30 and support toward $12.70 — roughly +31% from $17.05. Momentum favours further upside here.
Expect KLRA to range from $13.11 to $52.86 through 2040. The $26.30 average target implies a +54% move from current prices. That is up +18% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KLRA price prediction for 2050 points to an average of $52.89 (low $23.80, high $119.83) — a potential gain of +210% on today's $17.05. Momentum favours further upside here.
Investing $1,000 in KLRA today (≈ 58.651026 KLRA) could be worth
$3,102.16
+$2,102.16 (+210%) by 2050 · US Dollar
Based on the average projected KLRA price of $52.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KLRAwould be worth at today's price.
$1,000 invested in KLRA on Apr 17, 2026 (≈ 38.461538 KLRA) would be worth
$655.77
-$344.23 (-34.4%) today · 0.66× · US Dollar
Based on a KLRA entry price of $26 vs. today's $17.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.4 | $979.89 | -2.0% |
| 1 month ago | $22.03 | $773.94 | -22.6% |
| 3 months ago | $25.15 | $677.93 | -32.2% |
| All time ago | $26 | $655.77 | -34.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KLRA forecast.
Our base-case forecast reaches $34.00 around 2050.
Implied market cap at $34.00: $4.41B
The multi-year forecast shows a mixed but gradually improving path from 2026 onward. In 2026, the min is $17.91, the avg is $17.91, the max is $23.47, with a 0% ROI and neutral sentiment.
In 2027, the min is $12.77, the avg is $17.45, the max is $25.76, with a -2.5% ROI and neutral sentiment. In 2028, the min is $12.32, the avg is $17.85, the max is $28.05, with a -0.3% ROI and neutral sentiment.
From 2029 onward, the forecast turns more constructive, with 2029 at an avg of $20.08 and a max of $33.09 (ROI 12.1, neutral). The 2030 forecast shows an average of $23.81 with a max of $40.81 (ROI 32.9, bullish). Subsequent years vary, with 2031 at $22.20 avg (ROI 24, bullish) and 2033 at $22.64 avg (ROI 26.4, bullish); 2035 at $23.44 avg (ROI 30.9, bullish).
Longer horizons show stronger upside as 2040 offers an avg of $26.78 and a max of $57.81 (ROI 49.5, bullish), while 2050 projects an avg of $56.91 and a max of $130.90 (ROI 217.8, bullish). These numbers illustrate a trajectory of growing value potential with higher upper bounds, alongside elevated volatility risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $23.81, a low of $14.94, and a high of $40.81, with a 32.9% ROI and bullish sentiment.
Near term (2026–2028) forecasts are neutral with flat to modest moves (0% in 2026, -2.5% in 2027, -0.3% in 2028). The longer horizon (2030–2050) turns bullish with higher potential ROIs (up to 32.9% in 2030 and up to 217.8% by 2050). These are estimates and not guarantees.
The 2050 maximum forecast is $130.90, with an average of $56.91 and a 217.8% ROI, indicating a possible path to and beyond $100 within the forecast period.
The current price is $17.91 and the market cap is $2.32B.
The 30-day range is $14.28 to $22.46. The stock has a support level at $17.91 and a resistance level at $23.30.
Kailera Therapeutics, Inc. Community Discussion
0Share your Kailera Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.